AI steps in to settle debate: is new pill combo better than chemo for older leukemia patients?

This study is not a treatment itself but a research method. It will collect data from nearly 2,000 older adults (60-75) with acute myeloid leukemia (AML) to compare a new drug combination (venetoclax plus decitabine) against standard intensive chemotherapy. Using AI and statistical matching, researchers aim to see which approach leads to better remission rates and transplant success. The goal is to validate the new combo without needing a traditional randomized trial.